Concord Biotech Approves 1:1 Bonus Issue

Concord Biotech has approved its first-ever 1:1 bonus issue, subject to shareholder approval. Under the proposal, eligible shareholders will receive one additional fully paid-up equity share of ₹1 each for every one existing share held on the record date. The record date will be announced separately by the company’s board. Alongside the bonus issue, Concord Biotech has approved an increase in its authorised share capital from ₹11 crore to ₹22 crore by creating 11 crore additional equity shares. The bonus shares will be issued by capitalising the company’s share premium account, which stood at ₹81.97 crore as of March 31, 2026. The move will increase the company’s paid-up equity share count while maintaining the same proportionate ownership of existing shareholders. Concord Biotech’s board approved the corporate action on September 23, 2026. Disclaimer: The views expressed purely for educational and informational purposes and do not constitute financial advice or a recommendation to buy, sell, or hold any security